PCT/2001/45 - World Intellectual Property Organization
PCT/2001/45 - World Intellectual Property Organization
PCT/2001/45 - World Intellectual Property Organization
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>45</strong>/<strong>2001</strong><br />
20008 <strong>PCT</strong> Gazette - Section I - Gazette du <strong>PCT</strong> 8 Nov/nov <strong>2001</strong><br />
TJ TM); EP (AT BE CH CY DE DK ES FI<br />
FR GB GR IE IT LU MC NL PT SE TR); OA<br />
(BF BJ CF CG CI CM GA GN GW ML MR<br />
NE SN TD TG).<br />
(51) 7 A61K 31/00<br />
(11) WO 01/82913<br />
(21) <strong>PCT</strong>/JP01/03617<br />
(13) A2<br />
(22) 26 Apr/avr <strong>2001</strong> (26.04.<strong>2001</strong>)<br />
(25) en (26) en<br />
(30) 60/201,712 3 May/mai 2000<br />
(03.05.2000)<br />
US<br />
(43) 8 Nov/nov <strong>2001</strong> (08.11.<strong>2001</strong>)<br />
(54) OCULAR TENSION DEPRESSOR<br />
MEDICAMENT ABAISSANT LA PRES-<br />
SION OCULAIRE<br />
(71) SUCAMPO AG [CH/CH]; Graben 5,<br />
CH-6300 Zug (CH). FUJISAWA PHAR-<br />
MACEUTICAL CO., LTD. [JP/JP]; 4-7,<br />
Doshomachi 3-chome, Chuo-ku, Osaka-shi,<br />
Osaka 541-8514 (JP).<br />
(for all designated States except / pour tous<br />
les États désignés sauf US)<br />
(72, 75) UENO, Ryuji [JP/US]; 11025 Stanmore<br />
Drive, Potomac, Montgomery, MD 20854<br />
(US).<br />
(74) KOTANI, Etsuji et al. / etc.; Nichimen<br />
Building 2nd Floor, 2-2, Nakanoshima<br />
2-chome, Kita-ku, Osaka-shi, Osaka<br />
530-0005 (JP).<br />
(81) AU BR CA CN HU IN JP KR MX NO NZ<br />
PL RU US.<br />
(84) EP (AT BE CH CY DE DK ES FI FR GB GR<br />
IE IT LU MC NL PT SE TR).<br />
(51) 7 A61K 31/00<br />
(11) WO 01/82914<br />
(21) <strong>PCT</strong>/US01/13546<br />
(13) A2<br />
(22) 27 Apr/avr <strong>2001</strong> (27.04.<strong>2001</strong>)<br />
(25) en (26) en<br />
(30) 60/200,437 28 Apr/avr 2000<br />
(28.04.2000)<br />
US<br />
(43) 8 Nov/nov <strong>2001</strong> (08.11.<strong>2001</strong>)<br />
(54) TOPICAL ANESTHETIC/OPIOID FOR-<br />
MULATIONS AND USES THEREOF<br />
FORMULATIONS TOPIQUES A BASE<br />
D’ANESTHESIQUE ET D’OPIOIDE, ET<br />
UTILISATIONS ASSOCIEES<br />
(71) MEMORIAL SLOAN-KETTERING<br />
CANCER CENTER [US/US]; 460 East<br />
63rd Street, New York, NY 10021 (US).<br />
(for all designated States except / pour tous<br />
les États désignés sauf US)<br />
(72, 75) PASTERNAK, Gavril [US/US]; Apartment<br />
21M, 500 East 83rd Street, New York,<br />
NY 10028 (US). KOLESNIKOV, Yuri<br />
[US/US]; 38 Ridge Road,<br />
07626 (US).<br />
Cresskill, NJ<br />
(74) LEHNHARDT, Susan, K.; Frommer<br />
Lawrence & Haug LLP, 7<strong>45</strong> Fifth Avenue,<br />
New York, NY 10151 (US).<br />
(81) AE AG AL AM AT AU AZ BA BB BG BR<br />
BY BZ CA CH CN CO CR CU CZ DE DK<br />
DM DZ EE ES FI GB GD GE GH GM HR<br />
HU ID IL IN IS JP KE KG KP KR KZ LC<br />
LK LR LS LT LU LV MA MD MG MK MN<br />
MW MX MZ NO NZ PL PT RO RU SD SE<br />
SG SI SK SL TJ TM TR TT TZ UA UG US<br />
UZ VN YU ZA ZW.<br />
(84) AP (GH GM KE LS MW MZ SD SL SZ TZ<br />
UG ZW); EA (AM AZ BY KG KZ MD RU<br />
TJ TM); EP (AT BE CH CY DE DK ES FI<br />
FR GB GR IE IT LU MC NL PT SE TR); OA<br />
(BF BJ CF CG CI CM GA GN GW ML MR<br />
NE SN TD TG).<br />
(51) 7 A61K 31/00<br />
(11) WO 01/82915 (13) A2<br />
(21) <strong>PCT</strong>/US01/13701<br />
(22) 27 Apr/avr <strong>2001</strong> (27.04.<strong>2001</strong>)<br />
(25) en (26) en<br />
(30) 09/559,528 28 Apr/avr 2000 US<br />
(28.04.2000)<br />
(43) 8 Nov/nov <strong>2001</strong> (08.11.<strong>2001</strong>)<br />
(54) TRANS-CLITORAL ADMINISTRA-<br />
TION OF THERAPY<br />
ADMINISTRATION TRANSCLITORI-<br />
DIENNE D’UN TRAITEMENT<br />
(71, 72) NEAL, Gary, W. [US/US]; 200<br />
Fort Sanders West Boulevard, Suite 309,<br />
Knoxville, TN 37922 (US).<br />
(74) ZOLTICK, Martin, M.; Zoltick Technology<br />
Law Group, PLLC, 21515 Ridgetop Circle,<br />
Suite 200, Sterling, VA 20166 (US).<br />
(81) AE AG AL AM AT AU AZ BA BB BG BR<br />
BY BZ CA CH CN CR CU CZ DE DK DM<br />
DZ EE ES FI GB GD GE GH GM HR HU<br />
ID IL IN IS JP KE KG KP KR KZ LC LK<br />
LR LS LT LU LV MA MD MG MK MN MW<br />
MX MZ NO NZ PL PT RO RU SD SE SG SI<br />
SK SL TJ TM TR TT TZ UA UG UZ VN YU<br />
ZA ZW.<br />
(84) AP (GH GM KE LS MW MZ SD SL SZ TZ<br />
UG ZW); EA (AM AZ BY KG KZ MD RU<br />
TJ TM); EP (AT BE CH CY DE DK ES FI<br />
FR GB GR IE IT LU MC NL PT SE TR); OA<br />
(BF BJ CF CG CI CM GA GN GW ML MR<br />
NE SN TD TG).<br />
(51) 7 A61K 31/00<br />
(11) WO 01/82916<br />
(21) <strong>PCT</strong>/US01/14393<br />
(13) A2<br />
(22) 2 May/mai <strong>2001</strong> (02.05.<strong>2001</strong>)<br />
(25) en (26) en<br />
(30) 60/201,613 3 May/mai 2000<br />
(03.05.2000)<br />
US<br />
(43) 8 Nov/nov <strong>2001</strong> (08.11.<strong>2001</strong>)<br />
(54) COMBINATION THERAPEUTIC COM-<br />
POSITIONS AND METHODS OF USE<br />
COMPOSITIONS THERAPEUTIQUES<br />
COMBINEES ET LEURS METHODES<br />
D’UTILISATION<br />
(71) TULARIK INC. [US/US]; Two Corporate<br />
Drive, South San Francisco, CA 94080 (US).<br />
(for all designated States except / pour tous<br />
les États désignés sauf US)<br />
(72, 75) JAEN, Juan, C. [US/US]; 154 Los<br />
Robles Drive, Burlingame, CA 94010 (US).<br />
CHEN, Jin-Long [CN/US]; 101 Challenge<br />
Court, Foster City, CA 94404 (US).<br />
(74) SNYDER, Joseph, R.; Townsend and<br />
Townsend and Crew LLP, Two Embarcadero<br />
Center, 8th floor, San Francisco, CA<br />
94111-3834 (US) et al. / etc.<br />
(81) AE AG AL AM AT AU AZ BA BB BG BR<br />
BY BZ CA CH CN CR CU CZ DE DK DM<br />
DZ EE ES FI GB GD GE GH GM HR HU<br />
ID IL IN IS JP KE KG KP KR KZ LC LK<br />
LR LS LT LU LV MA MD MG MK MN MW<br />
MX MZ NO NZ PL PT RO RU SD SE SG SI<br />
SK SL TJ TM TR TT TZ UA UG US UZ VN<br />
YU ZA ZW.<br />
(84) AP (GH GM KE LS MW MZ SD SL SZ TZ<br />
UG ZW); EA (AM AZ BY KG KZ MD RU<br />
TJ TM); EP (AT BE CH CY DE DK ES FI<br />
FR GB GR IE IT LU MC NL PT SE TR); OA<br />
(BF BJ CF CG CI CM GA GN GW ML MR<br />
NE SN TD TG).<br />
(51) 7 A61K 31/00<br />
(11) WO 01/82917 (13) A2<br />
(21) <strong>PCT</strong>/US01/1<strong>45</strong>86<br />
(22) 3 May/mai <strong>2001</strong> (03.05.<strong>2001</strong>)<br />
(25) en (26) en<br />
(30) 60/201,601 3 May/mai 2000 US<br />
(03.05.2000)<br />
(43) 8 Nov/nov <strong>2001</strong> (08.11.<strong>2001</strong>)<br />
(54) TREATMENT OF HYPERTRIGLYC-<br />
ERIDEMIA AND OTHER CONDITIONS<br />
USING LXR MODULATORS<br />
TRAITEMENT DE L’HYPERTRIGLY-<br />
CERIDEMIE ET D’AUTRES MALA-<br />
DIES AU MOYEN DE MODULATEURS<br />
LXR<br />
(71) TULARIK INC. [US/US]; Two Corporate<br />
Drive, South San Francisco, CA 94080 (US).<br />
(for all designated States except / pour tous<br />
les États désignés sauf US)<br />
(72, 75) SHAN, Bei [US/US]; 349 Quay Lane,<br />
Redwood City, CA 94065 (US). SCHULTZ,<br />
Joshua [US/US]; 302 Amesport Landing,<br />
Half Moon Bay, CA 94019 (US). TU, Hua<br />
[CN/US]; 750 Glenview Drive, Apt. 307, San<br />
Bruno, CA 94066 (US).<br />
(74) GARRETT-WACKOWSKI, Eugenia;<br />
Townsend and Townsend and Crew LLP,<br />
Two Embarcadero Center, 8th Floor, San<br />
Francisco, CA 94111-3834 (US) et al. / etc.<br />
(81) AE AG AL AM AT AU AZ BA BB BG BR<br />
BY BZ CA CH CN CR CU CZ DE DK DM<br />
DZ EE ES FI GB GD GE GH GM HR HU<br />
ID IL IN IS JP KE KG KP KR KZ LC LK<br />
LR LS LT LU LV MA MD MG MK MN MW<br />
MX MZ NO NZ PL PT RO RU SD SE SG SI<br />
SK SL TJ TM TR TT TZ UA UG US UZ VN<br />
YU ZA ZW.<br />
(84) AP (GH GM KE LS MW MZ SD SL SZ TZ<br />
UG ZW); EA (AM AZ BY KG KZ MD RU<br />
TJ TM); EP (AT BE CH CY DE DK ES FI<br />
FR GB GR IE IT LU MC NL PT SE TR); OA<br />
(BF BJ CF CG CI CM GA GN GW ML MR<br />
NE SN TD TG).<br />
(51) 7 A61K 31/00<br />
(11) WO 01/82918<br />
(21) <strong>PCT</strong>/US01/40639<br />
(13) A2<br />
(22) 30 Apr/avr <strong>2001</strong> (30.04.<strong>2001</strong>)<br />
(25) en (26) en<br />
(30) 09/561,663 2 May/mai 2000<br />
(02.05.2000)<br />
US<br />
(43) 8 Nov/nov <strong>2001</strong> (08.11.<strong>2001</strong>)<br />
(54) METHOD FOR THE PREVENTION OF<br />
APOPTOSIS